Home>Topics>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals ALNY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. ROTH Capital's Debjit Chattopadhyay: Marriage Of Diagnostics To New Therapies Breeds Biotech Winners

      Headlines

      Fri, 25 Jul 2014

      By Life Sciences Report : Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends ...

    2. Alnylam And Benitec

      Headlines

      Fri, 25 Jul 2014

      By Pannobhaso : [Originally published on 6/16/2014] Alnylam and Benitec Alnylam (NASDAQ: ALNY ) is a $5.1B company and Benitec Biopharma ( OTCPK:BTEBY ) ( OTCPK:BNIKF ) is a $120M company. Both are biothech companies

    3. Tekmira Pharmaceuticals: Is The Clinical Hold Sell-Off A Buying Opportunity?

      Headlines

      Tue, 22 Jul 2014

      By Bio Terp : On July 3, 2014 , Tekmira (NASDAQ: TKMR ), "announced that the company has received verbal notice from the US FDA that the TKM-Ebola phase I healthy volunteer clinical study has been placed on clinical hold." Tekmira was in the process of conducting a phase I trial studying the ...

    4. Alnylam expands patent estate

      Headlines

      Tue, 22 Jul 2014

      The USPTO issues a notice of allowance to Alnylam's (NASDAQ: ALNY ) patent application 13/693,478. The allowed patent broadly covers single- or double-stranded chemically modified RNA therapeutics

    5. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

      Stock Reports

      Thu, 26 Jun 2014

      of options issued as a percentage of shares outstanding, putting shareholders at risk for future dilution. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class

    6. Alnylam and TAP collaborate on liver disease therapy

      Headlines

      Thu, 19 Jun 2014

      Foundation philanthropy subsidiary The Alpha-1 Project (TAP) enters into a collaboration agreement with Alnylam Pharmaceuticals ( ALNY -0.5% ) for the continued advancement of RNAi therapeutic ALN-AAT for the treatment of alpha-1 antitrypsin

    7. ALNY ’s Q1 as Expected; Strategic Deals and Pipeline Progress Underpin Improving Moat Trend

      Commentary

      Fri, 9 May 2014

      We're maintaining our $66 fair value estimate for Alnylam Pharmaceuticals after first-quarter results that were consistent with our expectations. While Alnylam continued to advance its broad RNAi pipeline

    8. I have orders in for....

      Commentary

      Sat, 8 Mar 2014

      Orders are in for the following; PRAN ARWR RLYP ALNY I have done some work looking at the newest holdings in both BIPIX and FBIOX, both great BIO TECH funds. My orders are based

    9. Maintaining Our Alnylam Fair Value as Lead Program Approaches Late-Stage Trials

      Commentary

      Fri, 8 Nov 2013

      We're maintaining our $42 fair value estimate for Alnylam Pharmaceuticals following third-quarter results that were in line with our expectations. Early in the third quarter, positive data for ALN

    10. Raising Our Alnylam Fair Value Estimate Based on Increased Confidence in Subcutaneous Technology

      Commentary

      Thu, 11 Jul 2013

      We're raising our fair value estimate for Alnylam ALNY to $42 per share from $31, as positive data for ALN-TTRsc came close on the heels of positive data for ALN-TTR02 earlier

    « Prev123Next »
    Content Partners